Acceleron Aerospace company information, Employees & Contact Information

Are Nuclear Propulsion Systems the Future of Space Exploration? Universe Today

Tag: acceleron fusion American Nuclear Society

Acceleron advances cold fusion technology Nuclear Engineering International

Acceleron Fusion Secures $24M Series A Led by Lowercarbon Capital and Collaborative Fund to Revolutionize Clean Energy with Muon-Catalyzed Fusion PRWeb

Acceleron Announces Partnership With Fiserv to Deliver Seamless Foreign Exchange Services Newswire.com

Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA BioSpace

Oracle Introduces New Cloud Networking Capabilities for Any Workload Oracle

Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts Fierce Pharma

Exclusive: Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals TechCrunch

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck BioPharma Dive

Merck picks up Acceleron for $11.5B drugdiscoverytrends.com

Merck agrees to acquire Acceleron Pharma for $11.5bn Pharmaceutical Technology

Merck to buy Acceleron for about $11.5 bln in rare disease drug push Reuters

Report: Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug BioSpace

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance Fierce Pharma

Acceleron and Braid Partner to Bring International Payment Automation to Community Financial Institutions and Drive Non-Interest Income Newswire.com

Acceleron soars on blood pressure data despite lengthy road to market BioPharma Dive

UPDATED: Merck cuts 143 jobs at Acceleron right on heels of $11.5B buyout Fierce Pharma

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention BioSpace

Novartis May Have a Suitor for Sandoz; Merck Closes Acceleron Deal BioSpace

Merck to Buy Acceleron Pharma for $11.5 Billion - WSJ The Wall Street Journal

Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial statnews.com

Merck will acquire Acceleron Pharma for $11.5 billion Chemical & Engineering News

Merck completes $11B Acceleron Pharma acquisition NJBIZ

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 Fierce Pharma

Bristol Myers Squibb engaged in Acceleron buyout talks but couldn't justify the price: report Fierce Pharma

Acceleron Corp Becomes a Digital Correspondent Bank Newswire.com

Acceleron dealt pipeline setback BioPharma Dive

Acceleron Abandons Charcot-Marie-Tooth Program After Trial Failure BioSpace

Yet another Acceleron investor challenges Merck's $11.5B acquisition offer: Bloomberg Fierce Pharma

Acceleron Stops Clinical Development of ACE-083 as Treatment for FSHD Muscular Dystrophy News

Bristol Myers, Acceleron's Reblozyl moves closer to blockbusterland with new blood disorders nod Fierce Pharma

Robert Zeldin to take post at Acceleron as its CMO retires Fierce Biotech

Acceleron's PAH drug sotatercept hits the mark in phase 2 Fierce Biotech

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy Fierce Biotech

Acceleron blood disease drug hits goal in pivotal clinical trial statnews.com

More activist pressure for Merck's $11.5B Acceleron deal as another hedge fund balks—but BMS appears ready to deal Fierce Pharma

Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefit Fierce Pharma

Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer Business Wire

Four firms shape Merck’s $11.5 bln bet on drugmaker Acceleron Reuters

Merck to buy Acceleron for about $11.5 billion in rare-disease drugs push CNBC

Seido Acceleron gravel wheelset review £950.00 off.road.cc

Acceleron to Develop Sotatercept in PAH drugdiscoverytrends.com

Merck to acquire Acceleron in a deal worth around $11.5bn PMLiVE

Post-acquisition, Merck to lay off 170 Acceleron employees The Business Journals

Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug Barron's

Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension Business Wire

Merck to buy Cambridge rare-disease specialist Acceleron for $11.5 billion The Boston Globe

Oracle expands Acceleron networking platform Tech Observer Magazine

J. Calnan & Assoc. celebrates grand opening of Acceleron Pharma's cGMP manufacturing facility NEREJ